E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Advanced Non Small Cell Lung Cancer with EGFR mutation |
CBNPC avancé porteur d’une mutation EGFR |
|
E.1.1.1 | Medical condition in easily understood language |
Advanced Lung cancer with EGFR mutation |
Cancer du poumon muté EGFR de stade avancé |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10029520 |
E.1.2 | Term | Non-small cell lung cancer stage IIIA |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10029522 |
E.1.2 | Term | Non-small cell lung cancer stage IV |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10029521 |
E.1.2 | Term | Non-small cell lung cancer stage IIIB |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Evaluating efficacy and toxicity of the combination of afatinib with cetuximab versus afatinib alone, in first-line treatment of patient with a EGFR mutated NSCLC |
Evaluer l’efficacité et la toxicité de l’association d’afatinib et cetuximab en comparaison à l’afatinib seul, en première ligne de traitement des CBNPC avec mutation EGFR |
|
E.2.2 | Secondary objectives of the trial |
Progression free survival Overall survival Response rate Progression free survival for patient with classical EGFR mutation (exon 19 deletion and L858R mutation) Toxicities (CTCAE 4.0 criteria) Quality of life (EQ-5D) |
• Survie sans progression • Survie globale • Taux de réponse objective et de contrôle de la maladie • Survie sans progression, survie globale et taux de réponse objective pour les patients porteurs de mutations EGFR classiques (délétions dans l’exon 19 et mutation L858R) • Toxicité (critères CTCAE 4.0) • Qualité de vie (EQ-5D)
|
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
BIO-IFCT-1503 (same protocol), objective : evaluating if detection and quantification of EGFR mutations in circulating DNA permit to appreciate the treatment response and the apparition of resistance. |
BIO-IFCT-1503 (voir protocole) : objectif : évaluer si la détection et la quantification des altérations d’EGR dans l’ADN circulant est un moyen non invasif d’apprécier la réponse au traitement et l’apparition de résistance avant les signes radiologiques.
|
|
E.3 | Principal inclusion criteria |
Stage III or IV NSCLC, non irradiable non operable Non squamous NSCLC histologically or cytologically confirmed No previous treatment of NSCLC EGFR mutation (exon 19 deletion, L858R mutation, G719X , L861Q orS768I mutations or exon 19 insertion) Presence of at least one lesion that can be measured PS 0 or 1 |
CBNPC de stade IV ou III, inaccessible à un traitement local (chirurgie ou radiothérapie) Diagnostic histologique ou cytologique de CBNPC non épidermoïde Absence de traitement anti-néoplasique antérieur systémique pour le CBNPC Présence d’une mutation EGFR détectée sur une plateforme INCa (délétions dans l’exon 19, mutation L858R, mutations G719X, L861Q, S768I ou insertions dans l’exon 19). Présence d’au moins une lésion mesurable PS 0 ou 1
|
|
E.4 | Principal exclusion criteria |
Symptomatic brain metastasis or requiring immediate radiotherapy T790M mutation or exon 20 insertion Radiotherapy less than 2 weeks prior randomization including symptomatic radiotherapy Interstitial pneumopathy |
Métastases cérébrales symptomatiques ou nécessitant une radiothérapie immédiate Présence d’une mutation EGFR T790M ou insertion dans l’exon 20 Radiothérapie datant de moins de 2 semaines, incluant la radiothérapie réalisée à titre symptomatique Présence d’une pneumopathie interstitielle diffuse sous-jacente
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Time to treatment failure Treatment failure is defined as treatment withdrawal regardless of the reason. |
Survie sans échec du traitement L’échec du traitement est défini par l’arrêt du traitement quelle qu’en soit la cause (incluant notamment les arrêts dus à une progression, un décès ou une toxicité). |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Progression free survival Overall survival Response rate Progression free survival for patient with classical EGFR mutation (exon 19 deletion and L858R mutation) Toxicities (CTCAE 4.0 criteria) Quality of life (EQ-5D) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 35 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
2 years after registration of the last subject to determine overall survival |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |